NCT06471218View on ClinicalTrials.gov

Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 2, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

June 30, 2025

Conditions
Hyperlipidemia
Interventions
DRUG

SHR-1918; SHR-1918 Placebo

SHR-1918/SHR-1918 Placebo,two administration

Trial Locations (1)

514031

Meizhou People's Hospital, Meizhou

All Listed Sponsors
lead

Beijing Suncadia Pharmaceuticals Co., Ltd

INDUSTRY

NCT06471218 - Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia | Biotech Hunter | Biotech Hunter